Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025)
Spero Therapeutics' (SPRO) quarterly Receivables - Net came in at $25.4 million in Q4 2025, down 48.66% YoY from $49.4 million in Q4 2024, and up 2821.54% on a QoQ basis from $868000.0 in Q3 2025.
Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025) Analysis & Trends
Spero Therapeutics (SPRO) has 3 years of Receivables - Net data on file, last reported at $25.4 million in Q4 2025.
- Quarterly Receivables - Net fell 48.66% year-over-year to $25.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.4 million (down 48.66% YoY) and the FY2025 annual result came in at $25.4 million, down 48.66% from the prior year.
- Receivables - Net climbed to $25.4 million in Q4 2025, from $868000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $50.8 million in Q2 2024 to a low of $868000.0 in Q3 2025.
- A 3-year average of $35.9 million and a median of $49.2 million in 2023 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2024 — Receivables - Net advanced 0.49% — and 2025, when it slumped 98.28%.
- Tracing SPRO's Receivables - Net over 3 years: stood at $49.2 million in 2023, then grew by 0.49% to $49.4 million in 2024, then plunged by 48.66% to $25.4 million in 2025.
- The last three Receivables - Net figures came in at $25.4 million (Q4 2025), $868000.0 (Q3 2025), and $24.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.36 Mn |
| Dec 31, 2025 | 25.36 Mn |
| Sep 30, 2025 | 868,000.00 |
| Sep 30, 2025 | 868,000.00 |
| Jun 30, 2025 | 24.45 Mn |
| Jun 30, 2025 | 24.45 Mn |
| Mar 31, 2025 | 23.61 Mn |
| Mar 31, 2025 | 23.61 Mn |
| Dec 31, 2024 | 49.39 Mn |
| Dec 31, 2024 | 49.39 Mn |
| Sep 30, 2024 | 50.59 Mn |
| Sep 30, 2024 | 50.59 Mn |
| Jun 30, 2024 | 50.76 Mn |
| Jun 30, 2024 | 50.76 Mn |
| Mar 31, 2024 | 49.20 Mn |
| Mar 31, 2024 | 49.20 Mn |
| Dec 31, 2023 | 49.15 Mn |
| Dec 31, 2023 | 49.15 Mn |